The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. United Therapeutics Corp shares valued at $3,142,718 were sold by MAHON PAUL A on Jun 26 ’25. At $285.70 per share, MAHON PAUL A sold 11,000 shares. The insider’s holdings dropped to 36,781 shares worth approximately $10.83 million following the completion of this transaction.
Also, PAUL MAHON purchased 11,000 shares, netting a total of over 3,142,718 in proceeds.
Before that, Mesa Nilda had sold 645 shares from its account. In a trade valued at $187,045, the Director traded United Therapeutics Corp shares for $289.99 each. Upon closing the transaction, the insider’s holdings decreased to 645 shares, worth approximately $1.44 million.
As published in their initiating research note from Cantor Fitzgerald on June 02, 2025, United Therapeutics Corp [UTHR] has been an Overweight and the price target has been revised to $405. Analysts at Wells Fargo downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal weight”‘ outlook in a report released in late April. As of April 21, 2025, BofA Securities has increased its “an Underperform” rating to a “Neutral” for UTHR. Earlier on July 11, 2024, Morgan Stanley downgraded its rating. Their new recommendation was “an Equal-weight” for UTHR stock which previously was a “an Overweight”.
Analyzing UTHR Stock Performance
On last trading session, United Therapeutics Corp [NASDAQ: UTHR] plunged -0.25% to $294.49. The stock’s lowest price that day was $291.13, but it reached a high of $298.3 in the same session. During the last five days, there has been a surge of approximately 3.66%. Over the course of the year, United Therapeutics Corp shares have dropped approximately -7.69%. Shares of the company reached a 52-week high of $383.51 on 02/19/25 and a 52-week low of $266.98 on 04/09/25.
Support And Resistance Levels for United Therapeutics Corp (UTHR)
According to the 24-hour chart, there is a support level at 290.98, which, if violated, would cause prices to drop to 287.47. In the upper region, resistance lies at 298.15. The next price resistance is at 301.81. RSI (Relative Strength Index) is 49.14 on the 14-day chart, showing neutral technical sentiment.
Is United Therapeutics Corp subject to short interest?
Stocks of United Therapeutics Corp saw a sharp steep in short interest on 2025-06-13 dropping by -0.48 million shares to 1.61 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 2.1 million shares. A decline of -29.77% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.46 of the overall float, the days-to-cover ratio (short ratio) decline to 2.46.
Which companies own the most shares of United Therapeutics Corp (UTHR)?
In terms of United Therapeutics Corp share price expectations, FactSet research, analysts set an average price target of 314 in the next 12 months, up nearly 6.36% from the previous closing price of $295.22. Analysts anticipate United Therapeutics Corp stock to reach 314 by 2025, with the lowest price target being 314. In spite of this, 7 analysts ranked United Therapeutics Corp stock as Buy at the end of 2025. On February 12, 2024, Goldman assigned a price target of “a Neutral” to the stock and upgraded coverage with a $215.
